HIF-1α mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma
- 1 June 2003
- journal article
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 116 (11), 2247-2260
- https://doi.org/10.1242/jcs.00427
Abstract
The acquisition of resistance to EGFR tyrosine kinase inhibitors (TKIs) remains a critical problem in lung cancer clinic, but the underlying mechanisms have remained incompletely understood. Although the TKI-induced or -selected genetic changes are known to drive resistance, resistance also occurs in tumor cells without genetic changes through poorly-characterized processes. Here, we show that the extracellular matrix (ECM) from various components of the tumor microenvironment, including neighboring tumor cells and fibroblasts, may be the driver of resistance in the absence of genetic changes. Unlike genetic changes, which may evolve during relatively long time of chronic EGFR TKI treatment to drive resistance, briefly culturing on de-cellularized ECM, or co-culturing with the ECM donor cells, immediately confers resistance to tumor cells that are otherwise sensitive to EGFR TKIs. We show evidence that collagen in the ECM may be its primary constituent driving resistance, at least partly through the collagen receptor Integrin-β1. Intriguingly, such effect of ECM and collagen is dose-dependent and reversible, suggesting a potential clinic-relevant application for targeting this effect. Collectively, our results reveal that the stromal ECM acts as a microenvironmental cue promoting EGFR TKI resistance in lung cancer cells, and targeting collagen and Integrin-β1 may be useful for treating resistance, especially the resistance without clearly-defined genetic changes, for which effective therapeutics are lacking. Citation Format: Ting Zhang, Lixia Guo, Yuanyuan Wang, Tao Ren, Yanan Yang. Stromal extracellular matrix is a microenvironmental cue promoting resistance to EGFR tyrosine kinase inhibitors in lung cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 122.Keywords
This publication has 48 references indexed in Scilit:
- Role of Phosphoinositide 3-Kinase in the Aggressive Tumor Growth of HT1080 Human Fibrosarcoma CellsMolecular and Cellular Biology, 2001
- Rac1 Activity Is Required for the Activation of Hypoxia-inducible Factor 1Journal of Biological Chemistry, 2001
- Hypoxia promotes oxidative base modifications in the pulmonary artery endothelial cell VEGF geneThe FASEB Journal, 2001
- Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinomaGut, 2001
- Identification of Alternative Spliced Variants of Human Hypoxia-inducible Factor-1αPublished by Elsevier ,2000
- Antagonising the expression of VEGF in pathological angiogenesisExpert Opinion on Therapeutic Patents, 1998
- Hypoxia Response Elements in the Aldolase A, Enolase 1, and Lactate Dehydrogenase A Gene Promoters Contain Essential Binding Sites for Hypoxia-inducible Factor 1Journal of Biological Chemistry, 1996
- Regulation of cytoskeletal functions by Rho small GTP-binding proteins in normal and cancer cellsCanadian Journal of Physiology and Pharmacology, 1996
- Purification and Characterization of Hypoxia-inducible Factor 1Journal of Biological Chemistry, 1995
- The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factorsCell, 1992